来凯医药-B(02105):美国食品药品监督管理局受理LAE118新药临床试验申请

智通财经
Jan 14

智通财经APP讯,来凯医药-B(02105)发布公告,美国食品药品监督管理局已经受理 LAE118的新药临床试验申请。LAE118是一种新型PI3Kα泛突变选择性抑制剂,用于治疗PIK3CA突变的实体瘤患者。公司将与监管机构紧密合作以完成相关申请。凭借其在临床开发和对外授权 LAE002(afuresertib)的良好及已验证的实绩,公司致力于为需要新型治疗方案的癌症患者提供这种精准治疗。

LAE118是一种新型PI3Kα泛突变选择性抑制剂。作为针对PIK3CA突变实体瘤的新型疗法,集团正积极推进此候选药物进入临床研究。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10